Troponin is a useful marker in clinical decision making in hospitalized patients with COVID-19 infections

BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The disease manifestations ranges from a mild common cold to severe disease and death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Safarnezhad-Tameshkel, Fahimeh, Motamed, Nima, Karbalaie Niya, Mohammad Hadi, Perumal, Dhayaneethie, Rezaie, Nader, Izadi, Shirin, Ranjbar, Mitra, Yadollahzadeh, Mahdi, Behdad, Behnam, Hemmasi, Gholamreza, Kaveh, Vahid, Anoushirvani, Ali Arash, Malek, Mojtaba, Farahani, Behzad, Eskandari, Ramin, Panahi, Mahshid, Rahimi, Mandana, Emami, Sepideh, Zamani, Farhad, Farrokhpour, Mohsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137218/
https://www.ncbi.nlm.nih.gov/pubmed/35686240
http://dx.doi.org/10.22122/arya.v17i0.2191
Descripción
Sumario:BACKGROUND: COVID-19 was introduced by the World Health Organization (WHO) as a global pandemic. The disease manifestations ranges from a mild common cold to severe disease and death. It has a higher mortality rate in people with a history of comorbidities, including cardiovascular disease (CVD) and can also contribute to cardiac injury. This study was conducted to evaluate the relationship between troponin levels as a cardiac marker and adverse outcomes in this disease. METHODS: The study sample included 438 patients hospitalized with COVID-19; however, the troponin data of 6 patients were not available. The need to be admitted to the intensive care unit (ICU), and death were considered the adverse outcome in patients with COVID-19. Troponin levels were checked in all patients on day 1 and day 3 of hospitalization. Multiple logistic regression analysis was performed to determine whether there was an independent association between the adverse outcomes and troponin enzyme in hospitalized patients with COVID-19. RESULTS: The mean age of patients was 61.29 ± 15.84 years. Among the 432 patients tested on day 1 of hospitalization, 24 patients (5.6%) tested positive (Troponin 1), and among the 303 patients tested on day 3, 13 patients (4.3%) tested positive (Troponin 2). Based on our results, Troponin 1 showed an independent association with both death (3.008 [95%CI = 1.091-8.290]; P = 0.033) and need for ICU admission (8.499 [95%CI = 3.316-21.788]; P < 0.001) in multiple logistic regression analysis. Moreover, the status of Troponin 2 had an independent significant association with both death (4.159 [95%CI = 1.156-14.961]; P = 0.029) and ICU admission (7.796 [95%CI = 1.954-31.097]; P = 0.004). CONCLUSION: Troponin showed a significant association with adverse outcomes in people who were hospitalized with COVID-19. The periodical assessment of this enzyme from the time of hospitalization may improve the clinical decision making of clinicians.

Ejemplares similares